A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients

Summary

This study investigates the effectiveness and safety of 12 weeks of treatment with JNJ-16269110 (R256918), in overweight and obese patients. The primary measure of effectiveness is the change in body weight at a clinically relevant dosage level during treatment. Additional measures include body mass index (BMI), DEXA (dual X-ray absorptiometry which is a specialized x-ray test that measures body composition), fasting glucose, lipid levels, and blood pressure. Safety assessments performed during the trial include laboratory tests, vital sign measurements, and adverse event reporting.

Timeline

Start

2007-11

Primary completion

2008-06

Completion

2008-06

Drugs

Indications